Galectin Therapeutics Gets Patent

Galectin Therapeutics Gets Patent

Galectin Therapeutics, a developer of therapeutics that target galectin proteins, said pre-market Wednesday it has received notice of allowance for a U.S. Patent for “Galacto-Rhamnogalacturonate compositions for the treatment of a number of diseases associated with elevated inducible nitric oxide synthase.” The patent’s principal claims cover method of use for GR-MD-02 in a broad category of diseases in which there is an inflammatory response characterized by an increase in the […]

Read More ˃
D.R. Horton Relocates Corporate Headquarters

D.R. Horton Relocates Corporate Headquarters

D.R. Horton, America’s Builder, said premarket Wednesday that it has relocated its corporate headquarters from Fort Worth, Texas, to a newly constructed office in Arlington, Texas. The company’s new six-acre campus features a four-story office building and connected parking garage and is conveniently located along the I-30 corridor. “We are excited about our new company-owned campus, which gives our corporate employees the ability to work more closely together on a […]

Read More ˃
CACI International Wins Contract

CACI International Wins Contract

CACI International (CACI), a simulation technology company, has been awarded a contract with a ceiling value of $94 million to provide automated testing system support services to the U.S. Air Force 309th Electronics Maintenance Group.The five-year award represents new and continuing work in the company’s logistics and material readiness market area. The Air Force 309th Electronics Maintenance Group repairs, overhauls, and modifies various aircraft systems and components, and supports programmed […]

Read More ˃
Coupa Software Price Target Raised at RBC

Coupa Software Price Target Raised at RBC

Coupa Software received a price-target increase Thursday from RBC Capital Markets ahead of the fiscal Q1 results expected Monday afternoon from the provider of a cloud-based, spend-management platform. The new price target is $40 per share, up from $35. In comparison, the stock closed Wednesday at $34.22. RBC kept its investment rating on the shares at outperform. For the quarter ended April 30, the mean estimate of analysts polled by […]

Read More ˃
Akebia Therapeutics Starts Phase 2 Study

Akebia Therapeutics Starts Phase 2 Study

Akebia Therapeutics said pre-market Wednesday it has dosed a first patient in a phase 2 study that will evaluate vadadustat in dialysis-dependent chronic kidney disease (DD-CKD) patients who are hyporesponsive to erythropoiesis-stimulating agents. Specifically, the company said the phase 2 study will assess the safety and efficacy of vadadustat versus active comparator epoetin alfa in 80 DD-CKD patients with ESA hyporesponse in the US. The study’s primary outcome measure will […]

Read More ˃